Inhibition of the renin-angiotensin system: is more better?
Inhibitors of the renin-angiotensin-aldosterone system (RAS) exert beneficial effects in diabetic nephropathy, but the possibility of regression of existing renal lesions remains to be investigated. Teles et al. tested the effects of the RAS inhibitor losartan in rats starting 10 months after induction of diabetes, when glomerular lesions were already present. They linked the reductions of proteinuria with regression of mesangial expansion. More advanced lesions were not affected. There were no dose-response renal effects of losartan.
Anderson
Sharon
S
Division of Nephrology and Hypertension, Oregon Health and Science University, Portland, Oregon, USA. anderssh@ohsu.edu
Komers
Radko
R
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000818:Animals; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007678:Kidney Glomerulus / Q000473:pathology; D019808:Losartan / Q000008:administration & dosage / Q000627:therapeutic use; D011507:Proteinuria / Q000188:drug therapy; D051381:Rats; D012084:Renin-Angiotensin System / Q000187:drug effects*; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D019808:Losartan